Umbralisib tosylate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for umbralisib tosylate and what is the scope of freedom to operate?
Umbralisib tosylate
is the generic ingredient in one branded drug marketed by Tg Theraps and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.Umbralisib tosylate has sixty-eight patent family members in thirty-one countries.
Summary for umbralisib tosylate
| International Patents: | 68 |
| US Patents: | 8 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 9 |
| Patent Applications: | 46 |
| DailyMed Link: | umbralisib tosylate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for umbralisib tosylate
Generic Entry Date for umbralisib tosylate*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for umbralisib tosylate
US Patents and Regulatory Information for umbralisib tosylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tg Theraps | UKONIQ | umbralisib tosylate | TABLET;ORAL | 213176-001 | Feb 5, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Tg Theraps | UKONIQ | umbralisib tosylate | TABLET;ORAL | 213176-001 | Feb 5, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Tg Theraps | UKONIQ | umbralisib tosylate | TABLET;ORAL | 213176-001 | Feb 5, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Tg Theraps | UKONIQ | umbralisib tosylate | TABLET;ORAL | 213176-001 | Feb 5, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| Tg Theraps | UKONIQ | umbralisib tosylate | TABLET;ORAL | 213176-001 | Feb 5, 2021 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for umbralisib tosylate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Africa | 201409329 | SELECTIVE PI3K DELTA INHIBITORS | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2014006572 | ⤷ Try a Trial | |
| European Patent Office | 3260455 | INHIBITEURS SÉLECTIFS DE PI3K DELTA (SELECTIVE PI3K DELTA INHIBITORS) | ⤷ Try a Trial |
| Denmark | 2870157 | ⤷ Try a Trial | |
| Croatia | P20191002 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
